(MENAFN) Swiss drugs giant Novartis said that it has launched a legal action against Glaxo Smith Kline claiming that its larger rival is infringing one of its patents, Reuters reported.
The move, which will be fiercely resisted by the British company, is the latest twist in a bitter dispute that centers on the techniques used to produce a set of vaccines aimed at preventing childhood illnesses, including bacterial meningitis.
The Swiss company claims that not only should its patent be allowed to stand, but that Glaxo is infringing its intellectual property. The British drug group has yet to formally respond to the action.
Glaxo is working with Rouse Legal, the specialist intellectual property law firm, on the dispute, while Novartis is being advised by McDermott, Will & Emery, an American law firm. All parties involved declined to comment.
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.